Top

Published in:

01-01-2010 | Letter

Insulin resistance and increased risk for malignant neoplasms: confounding of the data on insulin glargine

Authors: J. M. Nagel, U. Mansmann, K. Wegscheider, J. Röhmel

Published in: Diabetologia | Issue 1/2010

Excerpt

To the Editor: Hemkens et al. [1] studied the risk of malignant neoplasms and mortality in patients treated with human insulin or with one of three insulin analogues. In vitro experiments [2] demonstrated a potential association of insulin analogues with an increased risk of malignancies. Epidemiological corroboration of the in vitro findings would have major implications for diabetic patients worldwide. …

Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732–1744CrossRefPubMed

Kurtzhals P, Schaffer L, Sorensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005CrossRefPubMed

Scherbaum WA, Kiess W (eds) (2004) Epidemiologie und Verlauf des Diabetes mellitus in Deutschland. Available from www.deutsche-diabetes-gesellschaft.de/leitlinien/EBL_Epidemiologie_Update_2004.pdf, accessed 4 September 2009

Rathmann W, Giani G (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:2568–2569 author reply 2569CrossRefPubMed

Pocock SJ, Smeeth L (2009) Insulin glargine and malignancy: an unwarranted alarm. Lancet 374:511–513CrossRefPubMed

Jewell NP (2004) Statistics for epidemiology. Chapman & Hall/CRC, Boca Raton

Zendehdel K, Nyren O, Ostenson CG, Adami HO, Ekbom A, Ye W (2003) Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 95:1797–1800PubMed

LeRoith D, Novosyadlyy R, Gallagher EJ, Lann D, Vijayakumar A, Yakar S (2008) Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp Clin Endocrinol Diabetes 116(Suppl 1):S4–S6CrossRefPubMed

Title: Insulin resistance and increased risk for malignant neoplasms: confounding of the data on insulin glargine
Authors: J. M. Nagel
U. Mansmann
K. Wegscheider
J. Röhmel
Publication date: 01-01-2010
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 1/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-009-1535-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Insulin resistance and increased risk for malignant neoplasms: confounding of the data on insulin glargine

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2010

Genetic association analysis of LARS2 with type 2 diabetes

Effects of exenatide on circulating glucose, insulin, glucagon, cortisol and catecholamines in healthy volunteers during exercise

The interferon-induced helicase IFIH1 Ala946Thr polymorphism is associated with type 1 diabetes in both the high-incidence Finnish and the medium-incidence Hungarian populations

Differential relationship between physical activity and progression to diabetes by glucose tolerance status: the Inter99 Study

Efficacy of leptin therapy in the different forms of human lipodystrophy

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page